Poster shows increased medication adherence rates and lower healthcare costs
CHALFONT, PA – October 3, 2013 – Genomind, a personalized medicine company, is pleased to announce that they presented a poster of new data titled “Pharmacogenetic Testing Prompts Increased Medication Adherence and Reduced Healthcare Resource Utilization in Psychiatric Patients” at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, held September 30-October 2, 2013 in Philadelphia, Pennsylvania. The poster was shared on October 1, 2013.
The poster showcased results of a study with IMS Health indicating that patients who used the Genecept Assay had significantly increased medication adherence rates as compared to controls. In addition, a relative cost savings of 9.5% was observed over the four month trial period for patients who utilized the Assay compared to patients who did not. This equates to an annual cost savings of $1,827 per patient.
“This is the first study of the Assay assessing its impact on resource utilization and medication adherence.” said Dr. Jay Lombard, Chief Scientific Officer and Medical Director, Genomind. “This study provides real-world observational evidence that the Genecept Assay can lead to increased medication adherence and lower healthcare costs.”
This study provides new evidence that pharmacogenetic testing can inform treatment interventions, leading to increased medication adherence in otherwise difficult to treat patients. The observed increase in adherence was associated with a significant decrease in overall costs related to outpatient activity. The poster shows that pharmacogenetic testing may help reduce the elevated healthcare costs of this population by identifying effective therapies and increasing medication adherence, thus decreasing the need for excess healthcare services.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind